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journal homepage: http: / /www.kjms-onl ine.comLETTER TO THE EDITORSpontaneous hemoperitoneum in recurrent
jejunal gastrointestinal stromal tumor after
imatinib therapyDear Editor,
Spontaneous hemoperitoneum from recurrent metastatic
gastrointestinal stromal tumor (GIST) has been seldom re-
ported in the literature, and the appropriate management
is not conclusive. Herein we present a case of recurrent
jejunal GIST after complete resection. After 2 years of
tyrosine kinase inhibitor (TKI) therapy, abdominal disten-
sion, anemia, and presentation of Cullen’s sign (Fig. 1)
developed. Exploratory laparotomy revealed a massive
hemoperitoneum and a large amount of necrotic fragile
tumors.Figure 1. Marked abdominal distension and presentation of
Cullen’s sign (edema and bruising around the umbilicus)
revealed the development of hemoperitoneum before the
exploratory laparotomy. The insert shows great amounts of
necrotic fragile tumors (about 1800 g) disseminated in the
abdominal cavity and an evacuated massive spontaneous
hemoperitoneum.
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http://dx.doi.org/10.1016/j.kjms.2012.11.010In patients with inoperable GIST receiving imatinib, the
median time to progression is approximately 2 years. By
reducing the tumor burden, resection of the residual GIST
might delay or prevent the development of resistant
cloning and, theoretically, prolong the time to disease
progression. The median time to best response is 3.5
months, and there is little chance of tumor shrinkage after
9 months [1]. Some researchers have proposed surgical
intervention should be taken into consideration after 3e9
months of TKI therapy if the disease appears grossly
resectable [2]. In our case, general progression of recurrent
GIST during imatinib therapy revealed deterioration of
antitumor effect, which may be due to acquired resistance
from unproved additional mutation.
Tumor bleeding that required intensive treatment was
reported to occur in less than 5% of GIST patients who
underwent imatinib therapy [3]. The most important
symptom suggestive of ruptured GIST is abdominal pain,
particularly in association with anemia or hypovolemia [4].
To the best of our knowledge, this is the first case of
spontaneous hemoperitoneum during imatinib therapy
presenting with the unusual Cullen’s sign. Emergent surgery
may be encountered in acute management of internal
bleeding induced by imatinib. However, surgery may not be
satisfactory under this circumstance. Some authors suggest
that tumors become amenable to surgery with prior imati-
nib therapy, evolving necrosis and localized progression
could benefit from surgery to avoid life-threatening
complications. The genotype of c-kit mutation is
a possible factor indicating the risk of tumor rupture or
bleeding induced by imatinib, because the high respon-
siveness rapidly leads to tumor necrosis. In our case, the
large amount of necrotic fragile tumors and lack of gross
intact tumor structure found at operation seemed to
exhibit a correlation between spontaneous hemoper-
itoneum and the antitumor effect of imatinib.
Missing the appropriate time of surgical intervention
may lead to two consequences: (1) losing the opportunity toed by Elsevier Taiwan LLC. All rights reserved.
Editorial 403reduce the tumor burden to eliminate the chance of
developing secondary mutation that may result in acquired
resistance; and (2) increasing the risk of tumor rupture
from antitumor effect of imatinib or overgrowth of the GIST
resulting in life-threatening complications and unfavorable
emergent operation. We recommend surgery at 3e9 months
after initiation of imatinib therapy, when the TKIs are most
effective, for inoperable GIST if the tumor responds well to
the target therapy and is grossly resectable. However, more
frequent evaluation of the tumor receiving imatinib may be
necessary for early detection of large volumes of tumor
necrosis, which implies a high risk of tumor rupture and
fatal spontaneous hemoperitoneum. To advance the timing
of surgical resection may be the best policy in preventing
this dangerous situation.
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